GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease.
Javier Rodriguez-CarrioMercedes Alperi-LópezPatricia LópezÁngel I Pérez-ÁlvarezMiriam Gil-SerretNuria AmigoCatalina UlloaLorena BenaventeFrancisco J Ballina-GarcíaAna SuárezPublished in: Journal of clinical medicine (2020)
This study aimed at evaluating the clinical relevance of glycoprotein profiles during the earliest phases of rheumatoid arthritis (RA) as biomarkers of cardiovascular (CV) risk and treatment response. Then, GlycA and GlycB serum levels were measured using 1H-nuclear magnetic resonance in 82 early RA patients, 14 clinically-suspect arthralgia (CSA), and 28 controls. Serum glycosyltransferase activity was assessed by a colorimetric assay. Subclinical CV disease was assessed by Doppler-ultrasound. We found that GlycA and GlycB serum levels were increased in RA (both p < 0.001), but not in CSA, independently of cardiometabolic risk factors. Increased serum glycosyltransferase activity paralleled GlycA (r = 0.405, p < 0.001) and GlycB levels (r = 0.327, p = 0.005) in RA. GlycA, but not GlycB, was associated with atherosclerosis occurrence (p = 0.012) and severity (p = 0.001). Adding GlycA to the mSCORE improved the identification of patients with atherosclerosis over mSCORE alone, increasing sensitivity (29.7 vs. 68.0%) and accuracy (55.8 vs. 76.6%) and allowing reclassification into more appropriate risk categories. GlycA-reclassification identified patients with impaired lipoprotein metabolism. Finally, baseline GlycA levels predicted poor clinical response upon anti-rheumatic treatment at 6 and 12 months in univariate and multivariate analysis. In sum, increased GlycA levels during the earliest stage of RA can be considered a powerful biomarker for CV risk stratification and treatment response.
Keyphrases
- rheumatoid arthritis
- disease activity
- cardiovascular disease
- magnetic resonance
- ankylosing spondylitis
- interstitial lung disease
- risk factors
- end stage renal disease
- type diabetes
- risk assessment
- gold nanoparticles
- chronic kidney disease
- systemic lupus erythematosus
- ejection fraction
- nitric oxide
- newly diagnosed
- single cell
- coronary artery disease
- computed tomography
- patient reported outcomes
- replacement therapy
- fluorescent probe
- prognostic factors
- climate change
- cardiovascular risk factors
- combination therapy
- contrast enhanced